Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s)

National Institutes of Health (NIH)

Components of Participating Organizations

National Institute of Allergy and Infectious Diseases (NIAID)

Office of AIDS Research (OAR)

National Heart, Lung, and Blood Institute (NHLBI)

National Institute on Aging (NIA)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institute on Drug Abuse (NIDA)

National Institute of Mental Health (NIMH)

National Institute of Neurological Disorders and Stroke (NINDS)

 Applicants should carefully note which ICOs participate in this announcement and refer to NIH Institute, Center, and Office Grants & Funding Profiles for ICO-specific missions, interest areas, priorities, and funding considerations.

Funding Opportunity Title

HIV/AIDS Clinical Trials Network Clinical Trials Units (UM1 Clinical Trial Required)

Activity Code

UM1 Research Project with Complex Structure Cooperative Agreement

Announcement Type

Reissue of RFA-AI-19-045

Related Notices

Funding Opportunity Number (FON)

RFA-AI-28-004

Companion Funding Opportunity

RFA-AI-28-001 , UM1 Research Project with Complex Structure Cooperative Agreement
RFA-AI-28-002 , UM1 Research Project with Complex Structure Cooperative Agreement
RFA-AI-28-003 , UM1 Research Project with Complex Structure Cooperative Agreement

Number of Applications

See Part 2, Section III. 3. Additional Information on Eligibility.

Assistance Listing Number(s)

93.8RP, 93.HDR, 93.AGR, 93.310, 93.853, 93.242, 93.HL2, 93.DA1, 93.KRP, 93.DE1

Funding Opportunity Purpose

The purpose of this notice of funding opportunity (NOFO) is to support HIV/AIDS Clinical Trials Network Clinical Trials Units (CTUs). CTUs will provide the infrastructure, as well as the scientific and administrative expertise to conduct clinical studies developed by NIH HIV/AIDS Clinical Trials Networks to advance research in the prevention and treatment of HIV and HIV-associated diseases. CTUs will participate in multiple clinical research studies, accessing relevant populations most heavily impacted by the HIV/AIDS epidemic and studies of highest priority to NIH.

Funding Opportunity Goal(s)

NIH's mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability.

Key Dates

Posted Date

November 20, 2026

Open Date (Earliest Submission Date)

February 09, 2027
Application Due Dates Review and Award Cycles
New Renewal / Resubmission / Revision (as allowed) AIDS - New/Renewal/Resubmission/Revision, as allowed Scientific Merit Review Advisory Council Review Earliest Start Date
March 09, 2027 March 09, 2027 Not Applicable July 2027 October 2027 December 2027

All applications are due by 5:00 PM local time of applicant organization. 

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date

March 10, 2027

Due Dates for E.O. 12372

Not Applicable

Required Application Instructions

It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide, except where instructed to do otherwise (in this NOFO or in a Notice from NIH Guide for Grants and Contracts).

Conformance to all requirements (both in the How to Apply - Application Guide and the NOFO) is required and strictly enforced. Applicants must read and follow all application instructions in the How to Apply - Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the How to Apply - Application Guide, follow the program-specific instructions.

Applications that do not comply with these instructions may be delayed or not accepted for review.

There are several options available to submit your application through Grants.gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.

  1. Use the NIH ASSIST system to prepare, submit and track your application online.
  2. Use an institutional system-to-system (S2S) solution to prepare and submit your application to Grants.gov and eRA Commons to track your application. Check with your institutional officials regarding availability.
  3. Use Grants.gov Workspace to prepare and submit your application and eRA Commons to track your application.

Part 2. Full Text of Announcement

Section I. Notice of Funding Opportunity Description

Network Scope and Structure

The National Institute of Allergy and Infectious Diseases (NIAID) and its Institute, Center and Office (ICO) partners will support four clinical trials networks with unique research agendas that will conduct HIV/AIDS prevention, treatment and implementation science research improving uptake of evidence-based strategies across the lifespan: 

  1. HIV/AIDS Adult Therapeutics Clinical Trials Network
  2. HIV/AIDS Maternal, Adolescent and Pediatric Clinical Trials Network
  3. HIV Prevention Clinical Trials Network
  4. Immune-Based Prevention Clinical Trials Network

Each HIV/AIDS Clinical Trial Network is composed collectively of the following clinical trial infrastructure designed to support a complex clinical research agenda:

RFA-AI-28-001 - HIV/AIDS Clinical Trials Network Leadership and Operations Centers (LOCs)
RFA-AI-28-002 - HIV/AIDS Clinical Trials Network Laboratory Centers (LCs)
RFA-AI-28-003 - HIV/AIDS Clinical Trials Network Statistical and Data Management Centers (SDMCs)
RFA-AI-28-004 - HIV/AIDS Clinical Trials Network Clinical Trials Units (CTUs) – this notice of funding opportunity (NOFO)

While the emphasis of each Network is on clinical trials, clinical research studies that are not NIH-defined clinical trials are also in scope when undertaken to support the program. For this NOFO, the term "clinical study" refers to both clinical trials and clinical research studies, and "clinical trial" is used to refer to a clinical trial only.

Each Clinical Trials Network will have an Executive Management Committee (EMC), established by the LOC, to coordinate the activities of the Network's LOC, LC and SDMC.

NIAID is responsible for the oversight and safety of all study participants in clinical trials funded by NIAID and will provide NIAID-convened Data and Safety Monitoring Boards (DSMBs) to monitor clinical trials. NIAID will provide additional support services for Network trials under an Investigational New Drug (IND) or Investigational Device Exemption (IDE). 

Clinical Trials Unit Overview

The Clinical Trials Units (CTUs) are a core element of the HIV/AIDS Clinical Trials Networks that are structured to be an integrated unit with the demonstrated capacity to coordinate and execute clinical trials. CTUs are comprised of up to eight Clinical Research Sites (CRSs) supported by CRS pharmacy(ies) and CRS laboratory(ies). CRSs are discrete locations (e.g., hospital, clinics, community health centers, local health department clinics, etc.) with appropriate, identified and characterized potential trial participants where participant recruitment and retention, protocol management and other clinical research activities are conducted. Additional Protocol-Specific (PS) Clinical Research Sites may be added during the project period to rapidly address emerging Clinical Trial Network clinical research protocol needs and other NIH priorities.

CTUs employ robust regulatory assurance, data management, training, and quality management procedures and have demonstrated experience and/or capacity to support implementation science research. Each CTU provides scientific leadership, operational oversight, and infrastructure to support one or more HIV/AIDS Clinical Trials Networks. It functions as a cohesive, integrated unit with the capacity to conduct a broad range of clinical studies, in compliance with all applicable domestic and international regulations. International sites can offer opportunities for benefit to Americans living with, or at risk for acquiring, HIV and other HIV-associated infections when the proposed research cannot be accomplished as effectively or efficiently through domestic sites alone.

The Research Agendas for the four Networks are as follows: 

1. HIV/AIDS Adult Therapeutics Clinical Trials Network – Responsible for supporting the advancement of therapeutics research toward the treatment and cure of adults living with HIV including implementation science and clinical research to improve the management of HIV-related co-morbidities, coinfections and aging. Key aspects to this research agenda include: 

  • Implementation Science - strategies to adapt, deliver, and expand the reach, scale-up, and sustainability of evidence-based treatment for HIV and HIV-associated diseases. 
  • Novel and Durable Interventions for HIV – strategies to achieve durable HIV suppression and improve treatment outcomes for adults living with HIV. 
  • Anti-retroviral (ART)-Free Remission (HIV Cure) - strategies to eradicate HIV or sustain virologic remission through immune-based interventions. 
  • Complications and Non-Infectious Comorbidities – strategies to improve the prevention, treatment and management of high-impact co-morbidities in PWH (e.g., neurocognitive, substance use disorders, cardiovascular diseases, lung diseases, diabetic and related metabolic and endocrine conditions, kidney, urologic and hematologic disease, oropharyngeal complications, aging associated conditions). 
  • Viral Hepatitis - novel treatment strategies for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. 
  • Tuberculosis - novel therapeutics and combination treatments for drug-sensitive and -resistant tuberculosis (TB). 

Additionally, this Network will be responsible for the clinical research infrastructure to support early-stage pilot trials of novel products and approaches; opportunities for intensive sampling of potential tissue reservoirs of HIV; and specialized laboratory capabilities for virologic and immunologic analyses.   

2. HIV/AIDS Maternal, Adolescent, and Pediatric Clinical Trials Network – Responsible for advancing research to generate the evidence base on novel, innovative therapies, interventions, methods, and strategic approaches for HIV and HIV-associated conditions in infants, children, adolescents, and pregnant/postpartum women, integrating implementation science across the product development lifecycle to speed their adoption and scale-up.  Key aspects to this research agenda include: 

  • Implementation Science - strategies to adapt, deliver and scale evidence-based interventions that optimize prevention for pregnant and breastfeeding women, strengthen maternal antiretroviral therapy (ART), tailor infant prophylaxis, and expand early and repeat HIV testing for breastfeeding infants and children. 
  • HIV Treatment and Prevention Innovations - antiretroviral drug and regimen innovations in appropriate long-acting (or pediatric-friendly oral) formulations for pediatric and maternal populations and infant postnatal prophylaxis. 
  • ART-Free Remission (HIV Cure) - strategies to achieve sustained virologic remission in pediatric populations, including strategies initiated in the immediate newborn period. 
  • Treatment and Prevention of Tuberculosis and Other HIV-associated Co-Infections - new drugs and regimens for treatment and prevention of drug-sensitive and resistant TB disease, both pulmonary and extrapulmonary (including central nervous system [CNS]); address treatment needs for congenital syphilis, viral hepatitis (B and C), and other important HIV-associated co-occurring infections. 
  • Brain and Mental Health and Other HIV-associated Comorbidities - Neuroprotective and neurotoxic effects of ART to preserve neurocognitive development and mental health in infants, children, and adolescents. Evaluate novel preventive and therapeutic approaches for other high-priority diseases and co-occurring conditions 

3. HIV Prevention Clinical Trials Network – Responsible for advancing products and strategies to meet the needs of populations vulnerable to HIV acquisition including adults, adolescents and pregnant women, through the integration of biomedical, socio-behavioral and structural prevention strategies, in partnership with implementing agencies and organizations. Key aspects to this research agenda include: 

  • Implementation Science – strategies to optimize deployment of and improve access to biomedical and socio-behavioral evidence-based interventions for HIV prevention. 
  • Integrated Prevention Strategies - integration of socio-behavioral research to optimize HIV prevention outcomes tailored to the population and context, to improve HIV treatment uptake and adherence, retention in care, and reduction of HIV risk. 
  • Novel Biomedical HIV Prevention and Delivery Systems - strategies and delivery methods that meet the needs of varied populations and help address the challenges of adherence. Multipurpose technologies (MPTs) – products designed to simultaneously protect against multiple sexual and reproductive health issues and potentially medications to treat or prevent other health conditions. 
  • Intersection of HIV and Other Sexually Transmitted Infections (STIs) - prevention and treatment strategies to address interaction between HIV and STIs. 

4. Immune-Based Prevention Trials Network – Responsible for the discovery and advancement of immune-based strategies to protect against HIV infection and associated infectious diseases, including TB and STIs, through Phase 1–3 clinical trials designed to answer key immunologic research questions to inform future candidate design, define correlates of protection, and identify safe and efficacious preventative regimens. Key aspects to this research agenda include: 

  • Antibody-Mediated Prevention for HIV - design and conduct Phase 1–3 trials of passive immunization strategies.     
  • Induced-Immunity for Prevention of HIV Acquisition - evaluate immunogens, immune modulators and adjuvants; and combinations of immunogens with antiretroviral drugs and other HIV prevention modalities.  Conduct rapid, iterative "discovery medicine" trials to evaluate novel immunogens and adjuvants. 
  • Analytical Treatment Interruption (ATI) Strategies - studies in PWH to evaluate viral control to inform HIV immune-based prevention approaches and immunotherapy development. 
  • Immune-based Prevention Strategies Against Other HIV-associated Infectious Diseases - evaluate interventions against other infectious diseases (e.g., TB and STIs) and how these diseases may influence the safety and effectiveness of HIV prevention approaches. 
  • Integration of Implementation and Behavioral Science Research - integration across all stages of immune-based product development and evaluation, assessing acceptability and mode of intervention. 
  • Determinants of Immune Function and Intervention Effectiveness - evaluate how the microbiome, diet and environmental exposures share or alter immune function and the effectiveness of prevention interventions.  

Other Research Areas: Each Network may have the opportunity to contribute to the research agenda for support of the development of strategies, interventions, and products for the rapid response against other/emerging infectious diseases (not listed above) of public health importance and to implement clinical trials in support of this agenda. The research agenda for those efforts will be developed post-award through cross-network, joint leadership efforts in conjunction with NIAID and other NIH staff.

Core and Protocol Funds

Funding to carry out the network's research agenda falls into two categories:

Core Funds: initial fixed-base funding for infrastructure and salary support that is not protocol-specific. NIAID will provide core funds directly to the LOC, LC, SDMC and Network-affiliated CTUs on an annual basis. 

Protocol Funds (PF): support to conduct protocols, including protocol-specific infrastructure or other requirements needed to conduct protocols at a clinical research site. PF varies annually, depending on costs of ongoing protocols. NIAID anticipates providing PF directly to the LOC, LC, SDMC and Network-affiliated CTUs on an annual basis. 

The LOC will estimate PF needs for the network (salary and non-salary PF) based on communications with the LC, SDMC and CTUs/CRSs and submit an annual budget request to NIAID. 

During the project period, additional protocol-specific (PS) sites may be added as needed to execute a specific protocol. These will be reviewed individually and, if approved, supported via a vendor agreement.  These PS sites will be closed upon completion of the protocol.

Investigators proposing NIH-defined clinical trials may refer to the Research Methods Resources website for information about developing statistical methods and study designs.

See Section VIII. Other Information for award authorities and regulations.

Section II. Award Information

Funding Instrument

Cooperative Agreement: A financial assistance mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this NOFO.

Application Types Allowed

New
Renewal - Renewals of RFA-AI-19-045

The OER Glossary and the How to Apply - Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.

Clinical Trial?

Required: Only accepting applications that propose clinical trial(s).

Funds Available and Anticipated Number of Awards

NIAID and partner components intend to commit an estimated total of $60 M to fund 45 - 65 awards in FY2028.

Award Budget

Application budgets are not limited but need to reflect the actual needs of the proposed project based on the size/scope of the CTU.

Award Project Period

The project period must be 7 years.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.

Section III. Eligibility Information

1. Eligible Applicants

Eligible Organizations

Higher Education Institutions - Includes all types

  • Public/State Controlled Institutions of Higher Education
  • Private Institutions of Higher Education

Nonprofits Other Than Institutions of Higher Education

  • Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
  • Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

  • Small Businesses
  • For-Profit Organizations (Other than Small Businesses)

Local Governments

  • State Governments
  • County Governments
  • City or Township Governments
  • Special District Governments
  • Indian/Native American Tribal Governments (Federally Recognized)
  • Indian/Native American Tribal Governments (Other than Federally Recognized)

Federal Governments

  • Eligible Agencies of the Federal Government
  • U.S. Territory or Possession

Other

  • Independent School Districts
  • Public Housing Authorities/Indian Housing Authorities
  • Native American Tribal Organizations (other than Federally recognized tribal governments)
  • Faith-based or Community-based Organizations
  • Regional Organizations
  • Non-domestic (non-U.S.) Entities (Foreign Organizations)

Foreign Organizations/Foreign Collaborations

Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed. 

NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards.

Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.

CRSs that are located outside of the United States (U.S.) must be part of the applicant institution (e.g., foreign off-site campus/facility of a domestic or foreign applicant institution and not foreign subawards). Each CRS may only be included in one CTU application. 

Required Registrations

Applicant Organizations

Applicant organizations must complete and maintain the following registrations as described in the How to Apply - Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of a due date is not a valid reason for a late submission, please reference NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications for additional information

  • System for Award Management (SAM) – Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code. Foreign organizations must obtain a NATO Commercial and Government Entity (NCAGE) Code (in lieu of a CAGE code) in order to register in SAM.
    • Unique Entity Identifier (UEI)- A UEI is issued as part of the SAM.gov registration process. The same UEI must be used for all registrations, as well as on the grant application.
  • eRA Commons - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their Grants.gov registrations; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
  • Grants.gov – Applicants must have an active SAM registration in order to complete the Grants.gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s))

All PD(s)/PI(s) must have an eRA Commons account.  PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. Obtaining an eRA Commons account can take up to 2 weeks.

All PD(s)/PI(s) must be registered with ORCID. The personal profile associated with the PD(s)/PI(s) eRA Commons account must be linked to a valid ORCID ID. For more information on linking an ORCID ID to an eRA Commons personal profile see the ORCID topic in our eRA Commons online help.

Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. 

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the How to Apply - Application Guide.

2. Cost Sharing

This NOFO does not require cost sharing as defined in the NIH Grants Policy Statement NIH Grants Policy Statement Section 1.2 Definition of Terms.

3. Additional Information on Eligibility

Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time, per NIH Grants Policy Statement Section 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:

  • A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
  • A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
  • An application that has substantial overlap with another application pending appeal of initial peer review (see NIH Grants Policy Statement 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Section IV. Application and Submission Information

1. Requesting an Application Package

The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this NOFO. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

2. Content and Form of Application Submission

It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide except where instructed in this notice of funding opportunity to do otherwise (in this NOFO, in a policy notice, or other notice from NIH Guide for Grants and Contracts). Conformance to the requirements in the How to Apply - Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

Page Limitations

All page limitations described in the How to Apply – Application Guide and the Table of Page Limits must be followed, with the following additional instructions:

The Research Strategy must consist of the following sub-sections with the indicated page limits:

Sub-section A. Overview of the Clinical Trials Unit (CTU), one required - 30 pages

Sub-section B. Administrative and Financial Resource Management, one required - 6 pages

Sub-section C. Communication, one required - 6 pages

Sub-section D. CTU Evaluation, one required - 6 pages

Sub-section E. Clinical Research Site(s) (CRS), one required, maximum of eight - 30 pages each 

Instructions for Application Submission

The following section supplements the instructions found in the How to Apply – Application Guide and should be used for preparing an application to this NOFO.

SF424(R&R) Cover

All instructions in the How to Apply - Application Guide must be followed.

SF424(R&R) Project/Performance Site Locations

All instructions in the How to Apply - Application Guide must be followed.

SF424(R&R) Other Project Information

All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

Facilities & Other Resources

Provide the name and NIAID Clinical Research Management System [CRMS] site identification number (if applicable) for each proposed CRS (labeled CRS 1 through CRS 8). 

Facility

  • Clinic location, infrastructure, layout, equipment, and security to support efficient clinical research operations
  • Specialized capabilities at each location
  • Information technology (IT) infrastructure, including hardware, connectivity, bandwidth, and data security
  • Capacity to effectively support implementation science research studies

Pharmacy

  • Pharmacy location, infrastructure, storage, security, and inventory systems
  • Compliance with quality standards as described in United States Pharmacopeial Convention (USP) Chapters or their equivalent (e.g., compliance with ISO class 5 environment standards, etc.)
  • Identification of CRS(s) that the pharmacy supports
  • Specialized equipment or capabilities

Laboratory

  • Location, infrastructure, storage, security, and specialized capabilities.
  • Testing capacity or supporting laboratory (if no local lab) for: chemistry, histology, toxicology, hematology, immunology (including CD4 and serology), virology (HIV viral load, DNA, resistance genotyping), metabolic tests, microbiology, pharmacology, cytology, specimen processing, tuberculosis (TB) testing, and urinalysis

Describe existing and planned relationships with organizations which demonstrate capacity to effectively conduct implementation science research studies.

Describe administrative and outside support or resources available to ensure adequate staffing and infrastructure.

SF424(R&R) Senior/Key Person Profile

All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

Provide clearly defined roles for CTU staff to ensure effective performance across the administrative, managerial, and scientific functions required to carry out Network Clinical Trials. Identify the following individuals as Senior/Key Personnel: CTU PD(s)/PI(s), CTU Coordinator, CRS Leader(s), CRS Coordinator(s), and Pharmacist(s) of Record.

Within the Common Forms for Biographical Sketch and NIH Biographical Sketch Supplement, provide the following information:

  • CTU PD(s)/PI(s): Describe relevant experience leading and managing a complex HIV/AIDS clinical research program, including specific roles and responsibilities. Highlight experience overseeing and managing IND-level protocols and implementation science research conducted across multiple Clinical Research Sites, including scientific leadership, strategic planning, prioritization, and resource allocation within a highly regulated research environment.
  • CTU Coordinator: Describe experience demonstrating strong administrative and financial management, training, staff supervision, evaluation, and operational logistics within a complex clinical research program operating in a highly regulated environment. Experience should align with the size and scope of the proposed CTU structure. Include experience ensuring and advancing compliance across multiple, complex, IND-level clinical research protocols and implementation science research.
  • CRS Leader (for each proposed CRS): Describe substantial experience managing and ensuring compliance across multiple, complex, IND-level HIV/AIDS clinical research protocols and implementation science research, including specific roles and responsibilities. Include experience in training, supervising and evaluating staff, and managing operational logistics appropriate to the size and scope of the proposed CRS.
  • CRS Coordinator (for each proposed CRS): Describe relevant experience implementing and managing complex, IND-level clinical research protocols and implementation science research, including specific roles and responsibilities.
  • Pharmacist(s) of Record (for each proposed CRS): Describe licensure and relevant experience providing pharmaceutical oversight and support for clinical research programs conducting IND-level protocols within a highly regulated environment, including specific roles and responsibilities.

R&R Budget

All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

Only request Core Funds for the initial fixed-base funding, infrastructure and salary support that is not protocol-specific (e.g., administrative and management support, community education and engagement structures and activities, clinical quality management activities, record retention).

Do not request Protocol Funds (PF) (e.g., protocol-specific personnel salary, participant recruitment and retention, protocol required tests and evaluations, participant reimbursement, community education and engagement structures and activities, and protocol specimen shipment and storage). 

R&R Subaward Budget

All instructions in the How to Apply - Application Guide must be followed.

PHS 398 Cover Page Supplement

All instructions in the How to Apply - Application Guide must be followed.

PHS 398 Research Plan

All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

Research Strategy: The research strategy must consist of sub-sections A-E as designated below.

Sub-Section A: Overview of the Clinical Trials Unit (CTU)

  • Provide an organizational chart demonstrating an integrated approach to supporting the proposed HIV/AIDS Clinical Trials Network(s).
  • Describe how the proposed leadership structure and the leadership team's experience: (1) aligns with the proposed HIV/AIDS Networks, and (2) demonstrates the capacity to effectively manage a complex unit of the size and scope proposed.
  • Describe how the CTU is positioned to contribute to the proposed Network(s).
  • Briefly explain how the use of international sites will directly inform interventions or strategies to benefit Americans living with, or at risk for acquiring, HIV and other HIV-associated infections.
  • Describe lines of authority and staffing structure, including roles of CTU PD(s)/PI(s), CTU Coordinator, CRS Leader(s), CRS Coordinator(s), and Pharmacist(s) of Record.
  • Outline leadership structure and justification for aligning with the proposed NIH HIV/AIDS Clinical Trials Networks.
  • Without duplicating information provided in the Common Forms for Biographical Sketch and Current and Pending (Other) Support and NIH Biographical Sketch Supplement forms, summarize organizational leadership experience of the team over the past 5–7 years managing complex multicenter HIV/AIDS trials. 
  • Describe strengths, challenges, and lessons learned from managing complex clinical trials in relevant participant populations, including implementation science research.
  • Describe the CTU's ability to effectively work within their regulatory environment, including maintaining compliance and keeping current with new regulations.
  • Describe processes for protocol selection including how decisions are made to allocate resources to support protocol implementation. 
  • Describe proposed staff contribution to Network protocol teams and committees.
  • Describe how the CTU structure is cohesive, synergistic, and integrated, and how this integration is present within each of the elements and across the entire CTU.

For renewal applications, include Progress Reports in Sub-Section A. 

Sub-section B. Administrative and Financial Resource Management

  • Outline financial management structure and staffing.
  • Describe strategies for optimizing productivity, cost containment measures, including shared infrastructure, if applicable.
  • Detail financial monitoring procedures, and plans for communicating resource allocation to CRS(s).

Sub-section C. Communication

  • Describe internal communication systems, including conflict resolution and decision dissemination.
  • Outline proposed communication with other Network elements (i.e., LOC, LC, SDMC).
  • Describe the process for communication with NIAID Division of AIDS (DAIDS) staff.
  • Detail processes for communicating study results to staff, participants, and communities.

Sub-section D. CTU Evaluation

  • Describe processes for assessing CRS readiness and compliance (e.g., U.S. Food and Drug Administration (FDA), International Council for Harmonisation (ICH)/Good Clinical Practice (GCP), NIAID, DAIDS, regulatory requirements).
  • Outline CRS preparation for protocol implementation.
  • Describe plans for evaluation and performance monitoring metrics, reporting frequency, and continuous improvement processes.
  • Define Clinical Research Site capacity thresholds and resource escalation procedures.
  • Outline close-out procedures for underperforming CTU elements.

Sub-section E. Clinical Research Sites (CRS) (minimum of 1, maximum of 8)

Applications proposing more than 8 CRSs will be considered non-compliant and will not be reviewed.

For each CRS, provide an organizational chart and describe the following:

  • Staffing plan and team leadership experience overseeing IND-level multi-site clinical trials (past 5 – 7 years). 
  • Previous experience conducting IND-level clinical trials (past 5 – 7 years), include study types, enrollment, retention, data quality, timelines).  Identify previous challenges executing clinical trials and approaches to overcoming these challenges.
  • Overall quality management structure, including details about QC/QA processes, metrics, evaluation frequency, Corrective and Preventative Actions (CAPA) procedures, and continuous improvement processes.
  • Approaches to assessing, developing, delivering and evaluating training needs.
  • Mentoring and continuing education plans.
  • IRB and regulatory approval processes including timelines. Describe challenges and mitigation strategies.
  • Do not name additional Protocol-Specific (PS) Clinical Research Sites (sites that may be added during the project period to rapidly address emerging Clinical Trial Network clinical research protocol needs) in the application.

Research Agenda / Implementation Science Research Capacity

  • Describe and justify the proposed Network affiliation(s). Describe how coordination across Networks (if applicable) will be addressed, including strategies to ensure operational efficiencies. 
  • Provide a description of existing and/or planned collaborations with partner organizations focused on implementation science research.
  • Describe experience conducting implementation science research in the past 5 – 7 years, including challenges and approaches to overcoming them. 
  • Describe how the clinical experience of each CRS contributes to the conduct of complex clinical trials in relevant participant populations.
  • Describe previous experience of the CRSs with recruitment and retention of clinical trial participants within relevant participant populations.

Community Engagement

  • Describe Good Participatory Practice (GPP)-aligned community engagement and input plans along with organizational structure, including dedicated staff supporting community activities.
  • Define Community Advisory Board (CAB) roles, composition, elections, jurisdiction, and meeting frequency.  Describe CRS-community relationships and outreach as well as CAB training and communication processes.
  • Describe how CAB activities will be evaluated and financial support allocated, as appropriate.

CRS Pharmacy

  • Describe the pharmacy structure, centralized activities (if any), and reporting lines (a diagram is recommended).
  • Provide a staffing plan, team experience, expertise and licensures/certifications, and integration of the Pharmacist(s) of Record into the CTU.
  • Outline oversight and communication processes.
  • Describe SOP development, pharmacy operations and study product management.
  • Outline pharmacy QC/QA activities, processes, procedures and regulatory compliance.

CRS Laboratory

  • Describe the laboratory structure, centralized functions, and integration into the CTU (diagram recommended).
  • Provide a staffing plan, certifications, and oversight processes.
  • Outline specimen management procedures to ensure proper specimen chain of custody, specimen tracking, local specimen storage capabilities, and specimen shipment processes.
  • Describe SOP development and regulatory compliance.
  • Describe material import/export challenges related to reliably maintaining test reagent inventories, equipment maintenance, and shipping study samples out of a country (if applicable).
  • Describe GCLP compliance across laboratories and associated clinics.

CRS Data Stewardship

  • Describe structure, reporting lines, and centralized functions.
  • Describe staffing, data quality assurance roles and coordination with the SDMC.
  • Detail data capture and eCRF procedures.
  • Describe IT infrastructure, data security, access controls, backup systems, and Electronic Health Records (EHR) access, if applicable, for NIAID monitoring contractors.

Letters of Support: Provide letters of support necessary to demonstrate the commitment of collaborators who have a significant role in the application. Do not submit letters of Network support.

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the How to Apply - Application Guide.

Other Plan(s): 

All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

  • A Data Management and Sharing Plan (DMS Plan) is required for any NIH-funded or conducted research that will generate scientific data. Applicants must submit the DMS Plan at the time of application using the NIH DMS Plan Format Page. The DMS Plan must address the elements in the structured format. Where the DMS Plan Format Page requires a "Yes or No" response, no additional narrative is allowed.

Appendix: Only limited Appendix materials are allowed. Follow all instructions for the Appendix as described in the How to Apply - Application Guide.

  • No publications or other material, with the exception of blank questionnaires or blank surveys, may be included in the Appendix.

PHS Human Subjects and Clinical Trials Information

When involving human subjects research, clinical research, and/or NIH-defined clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the How to Apply - Application Guide, with the following additional instructions:

Other Requested Information

For Renewal applications with ongoing clinical studies, applicants must include a list of all ongoing clinical studies and/or the unique ClinicalTrials.gov identifiers. All information must be combined in one single attachment using the filename "Ongoing Clinical Studies". If appropriate, please indicate for each study the NIAID Division of AIDS (DAIDS)-defined study status.

If you answered "Yes" to the question "Are Human Subjects Involved?" on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the How to Apply - Application Guide must be followed with the following additional instructions:

Although applicants must be prepared for clinical trials, definite plans for such involvement will not be possible at time of application. A Study Record MUST not be completed.

Delayed Onset Study

Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

All Applications must add and complete the Delayed Onset Study record and must check box "Anticipated Clinical Trial?".

Study Title: use "Multiple Delayed-Onset Studies"

Justification Attachment: Indicate that each clinical study protocol developed during the project period will be subject to approval through a procedure that involves an initial concept submission and subsequent review by the HIV/AIDS Clinical Trials Network and NIAID. If the concept receives approval, the next stage will be development of the protocol, which also must undergo review and approval prior to implementation through the HIV/AIDS Clinical Trials Network.

PHS Assignment Request Form

All instructions in the How to Apply - Application Guide must be followed.

Foreign Organizations

Foreign (non-U.S.) organizations must follow policies described in the NIH Grants Policy Statement, and procedures for foreign organizations described throughout the How to Apply Application Guide.

3. Unique Entity Identifier and System for Award Management (SAM)

See Part 2. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov

4. Submission Dates and Times

Part I. contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.

Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH's electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time.  If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications.

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the How to Apply – Application Guide.

5. Intergovernmental Review (E.O. 12372)

This initiative is not subject to intergovernmental review.

6. Funding Restrictions

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable only as described in the NIH Grants Policy Statement Section 7.9.1 Selected Items of Cost.

  • Awards issued under this notice of funding opportunity (NOFO) will be incrementally funded awards and may be issued for project periods of up to 7 years. Multi-year funded grants will not be allowed.
  • Grants awarded under this NOFO will not be provided the authority to automatically extend the final budget period one time to 12 months beyond the original project period end date shown in the Notice of Award. All extensions, including the first extension, will require prior approval. Please note a 7-year grant does not qualify for a no-cost extension.
  • Progress and financial reporting will be required and reviewed annually. All funds must be expended within the approved project period.

7. Other Submission Requirements and Information

Applications must be submitted electronically following the instructions described in the How to Apply - Application Guide. Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply – Application Guide. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.

Important reminders:

All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this NOFO for information on registration requirements.

The applicant organization must ensure that the unique entity identifier provided on the application is the same identifier used in the organization's profile in the eRA Commons and for the System for Award Management. Additional information may be found in the How to Apply - Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by components of participating organizations, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed. 

Mandatory Disclosure

Recipients or subrecipients must submit any information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. See Mandatory Disclosures, 2 CFR 200.113 and NIH Grants Policy Statement Section 4.1.36.

Send written disclosures to the NIH Chief Grants Management Officer listed on the Notice of Award for the IC that funded the award and to the HHS Office of Inspector Grant Self Disclosure Program at grantdisclosures@oig.hhs.gov. 

Post Submission Materials

Applicants are required to follow the instructions for post-submission materials, as described in the policy

Section V. Application Review Information

1. Criteria

Only the review criteria described below will be considered in the review process.  Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.

A proposed Clinical Trial application may include study design, methods, and intervention that are not by themselves innovative but address important questions or unmet needs. Additionally, the results of the clinical trial may indicate that further clinical development of the intervention is unwarranted or lead to new avenues of scientific investigation.

Overall Impact

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

Scored Review Criteria

Reviewers will consider each of the review criteria below in the determination of scientific merit and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

 

Does the project address an important problem or a critical barrier to progress in the field? Is the prior research that serves as the key support for the proposed project rigorous? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

Are the scientific rationale and need for a clinical trial to test the proposed hypothesis or intervention well supported by preliminary data, clinical and/or preclinical studies, or information in the literature or knowledge of biological mechanisms? For trials focusing on clinical or public health endpoints, is this clinical trial necessary for testing the safety, efficacy or effectiveness of an intervention that could lead to a change in clinical practice, community behaviors or health care policy? For trials focusing on mechanistic, behavioral, physiological, biochemical, or other biomedical endpoints, is this trial needed to advance scientific understanding?

Specific to this NOFO:

  • How well is the CTU positioned to contribute to the proposed Network? 

 

Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?

With regard to the proposed leadership for the project, do the PD/PI(s) and key personnel have the expertise, experience, and ability to organize, manage and implement the proposed clinical trial and meet milestones and timelines? Do they have appropriate expertise in study coordination, data management and statistics? For a multicenter trial, is the organizational structure appropriate and does the application identify a core of potential center investigators and staffing for a coordinating center?

Specific to this NOFO:

  • How well does/do the CTU PD(s)/PI(s) demonstrate experience and/or capacity to oversee and manage implementation science research studies?
  • How well does the leadership team's experience align with the proposed Networks?

 

Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

Does the design/research plan include innovative elements, as appropriate, that enhance its sensitivity, potential for information or potential to advance scientific knowledge or clinical practice?


 

Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators included plans to address weaknesses in the rigor of prior research that serves as the key support for the proposed project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?

If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex, race, and ethnicity, as well as the inclusion or exclusion of individuals of all ages (including children and older adults), justified in terms of the scientific goals and research strategy proposed?

Does the application adequately address the following, if applicable?

Study Design

Is the study design justified and appropriate to address primary and secondary outcome variable(s)/endpoints that will be clear, informative and relevant to the hypothesis being tested? Is the scientific rationale/premise of the study based on previously well-designed preclinical and/or clinical research? Given the methods used to assign participants and deliver interventions, is the study design adequately powered to answer the research question(s), test the proposed hypothesis/hypotheses, and provide interpretable results? Is the trial appropriately designed to conduct the research efficiently? Are the study populations (size, sex, age, demographic group), proposed intervention arms/dose, and duration of the trial, appropriate and well justified?

Are potential ethical issues adequately addressed? Is the process for obtaining informed consent or assent appropriate? Is the eligible population available? Are the plans for recruitment outreach, enrollment, retention, handling dropouts, missed visits, and losses to follow-up appropriate to ensure robust data collection? Are the planned recruitment timelines feasible and is the plan to monitor accrual adequate? Has the need for randomization (or not), masking (if appropriate), controls, and inclusion/exclusion criteria been addressed? Are differences addressed, if applicable, in the intervention effect due to sex and race/ethnicity?

Are the plans to standardize, assure quality of, and monitor adherence to, the trial protocol and data collection or distribution guidelines appropriate? Is there a plan to obtain required study agent(s)? Does the application propose to use existing available resources, as applicable?

Data Management and Statistical Analysis

Are planned analyses and statistical approach appropriate for the proposed study design and methods used to assign participants and deliver interventions? Are the procedures for data management and quality control of data adequate at clinical site(s) or at center laboratories, as applicable? Have the methods for standardization of procedures for data management to assess the effect of the intervention and quality control been addressed? Is there a plan to complete data analysis within the proposed period of the award?

Specific to this NOFO:

  • How effectively does the CTU structure demonstrate a cohesive, synergistic, and integrated unit, and is the integration evident within each of the elements and across the entire CTU?
  • How well does the proposed leadership structure demonstrate the capacity to effectively manage a complex unit of the size and scope proposed?
  • How well does the CTU demonstrate a robust plan for evaluation, including assessment and monitoring of capacity, and strategies for improving performance across all elements of the CTU?
  • To what extent does each CRS contribute to the proposed affiliated Network research agenda based on demonstrated experience conducting complex clinical trials in relevant participant populations?
  • How adequate are the plans to engage and receive input from the community?
  • How appropriately does the application address the overall structure and function of the CTU as well as the demonstrated experience and capacity to implement, manage, recruit and retain the key populations into the Clinical Trials Network protocols? 

 

Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

If proposed, are the administrative, data coordinating, enrollment and laboratory/testing centers, appropriate for the trial proposed?

Does the application adequately address the capability and ability to conduct the trial at the proposed site(s) or centers? Are the plans to add or drop enrollment centers, as needed, appropriate?

If international site(s) is/are proposed, does the application adequately address the complexity of executing the clinical trial?

If multi-sites/centers, is there evidence of the ability of the individual site or center to: (1) enroll the proposed numbers; (2) adhere to the protocol; (3) collect and transmit data in an accurate and timely fashion; and, (4) operate within the proposed organizational structure?

Specific to this NOFO:

  • To what extent do the existing and proposed relationships with facilities demonstrate the capacity to effectively support implementation science research studies?
  • How well does the CTU demonstrate the ability to effectively work within their regulatory environment, including maintaining compliance and keeping current with new regulations?

Additional Review Criteria

As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.

 

Is the study timeline described in detail, taking into account start-up activities, the anticipated rate of enrollment, and planned follow-up assessment? Is the projected timeline feasible and well justified? Does the project incorporate efficiencies and utilize existing resources (e.g., CTSAs, practice-based research networks, electronic medical records, administrative database, or patient registries) to increase the efficiency of participant enrollment and data collection, as appropriate?

Are potential challenges and corresponding solutions discussed (e.g., strategies that can be implemented in the event of enrollment shortfalls)?


 

For research that involves human subjects but does not involve one of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.


 

When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for inclusion. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research. 


 

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following three points: (1) a complete description of all proposed procedures including the species, strains, ages, sex, and total numbers of animals to be used; (2) justifications that the species is appropriate for the proposed research and why the research goals cannot be accomplished using an alternative non-animal model; and (3) interventions including analgesia, anesthesia, sedation, palliative care, and humane endpoints that will be used to limit any unavoidable discomfort, distress, pain and injury in the conduct of scientifically valuable research. Methods of euthanasia and justification for selected methods, if NOT consistent with the American Veterinary Medical Association (AVMA) Guidelines for the Euthanasia of Animals, is also required but is found in a separate section of the application. For additional information on review of the Vertebrate Animals Section, please refer to the Worksheet for Review of the Vertebrate Animals Section.


 

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.


 

For Resubmissions (as applicable), the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.


 

For Renewals (as applicable), the committee will consider the progress made in the last funding period.


 

For Revisions (as applicable), the committee will consider the appropriateness of the proposed expansion of the scope of the project. If the Revision application relates to a specific line of investigation presented in the original application that was not recommended for approval by the committee, then the committee will consider whether the responses to comments from the previous scientific review group are adequate and whether substantial changes are clearly evident.


Additional Review Considerations

As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.

 

Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.


 

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).


 

Reviewers will comment on whether the Resource Sharing Plan(s) (e.g., Sharing Model Organisms) or the rationale for not sharing the resources, is reasonable.


 

For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.


 

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.


2. Review and Selection Process

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by CSR, in accordance with NIH peer review policies and practices, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

As part of the scientific peer review, all applications will receive a written critique.

Applications may undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.

Requests for reconsideration of initial peer review will not be accepted for applications submitted in response to this NOFO. 

Applications will be assigned on the basis of established referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this NOFO. Following initial peer review, recommended applications will receive a second level of review by the appropriate national Advisory Council or Board. Funding decisions are based on the core tenets of a unified funding strategy, see ICO Funding Policies and Considerations. Applicants are strongly encouraged to also refer to the ICO-specific funding policies and considerations pages linked therein that build upon the agency-wide framework.

If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement Section 2.5.1. Just-in-Time Procedures. This request is not a Notice of Award nor should it be construed to be an indicator of possible funding.

Prior to making an award, NIH reviews an applicant's federal award history in SAM.gov to ensure sound business practices. An applicant can review and comment on any information in the Responsibility/Qualification records available in SAM.gov.  NIH will consider any comments by the applicant in the Responsibility/Qualification records in SAM.gov to ascertain the applicant's integrity, business ethics, and performance record of managing Federal awards per 2 CFR Part 200.206 "Federal awarding agency review of risk posed by applicants."  This provision will apply to all NIH grants and cooperative agreements except fellowships.

3. Anticipated Announcement and Award Dates

After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.

Information regarding the disposition of applications is available in the NIH Grants Policy Statement Section 2.4.4 Disposition of Applications.

Section VI. Award Administration Information

1. Award Notices

A Notice of Award (NoA) is the official authorizing document notifying the applicant that an award has been made and that funds may be requested from the designated HHS payment system or office. The NoA is signed by the Grants Management Officer and emailed to the recipient's business official.

In accepting the award, the recipient agrees that any activities under the award are subject to all provisions currently in effect or implemented during the period of the award, other Department regulations and policies in effect at the time of the award, and applicable statutory provisions.

Recipients must comply with any funding restrictions described in Section IV.6. Funding Restrictions. Any pre-award costs incurred before receipt of the NoA are at the applicant's own risk.  For more information on the Notice of Award, please refer to the NIH Grants Policy Statement Section 5. The Notice of Award and NIH Grants & Funding website, see Award Process.

Individual awards are based on the application submitted to, and as approved by, the NIH and are subject to the IC-specific terms and conditions identified in the NoA.

ClinicalTrials.gov: If an award provides for one or more clinical trials. By law (Title VIII, Section 801 of Public Law 110-85), the "responsible party" must register and submit results information for certain "applicable clinical trials" on the ClinicalTrials.gov Protocol Registration and Results System Information Website (https://register.clinicaltrials.gov). NIH expects registration and results reporting of all trials whether required under the law or not. For more information, see https://grants.nih.gov/policy/clinical-trials/reporting/index.htm

Institutional Review Board or Independent Ethics Committee Approval: Recipient institutions must ensure that all protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the recipient must provide NIH copies of documents related to all major changes in the status of ongoing protocols.

Data and Safety Monitoring Requirements: The NIH policy for data and safety monitoring requires oversight and monitoring of all NIH-conducted or -supported human biomedical and behavioral intervention studies (clinical trials) to ensure the safety of participants and the validity and integrity of the data. Further information concerning these requirements is found at http://grants.nih.gov/grants/policy/hs/data_safety.htm and in the application instructions (SF424 (R&R) and PHS 398).

Investigational New Drug or Investigational Device Exemption Requirements: Consistent with federal regulations, clinical research projects involving the use of investigational therapeutics, vaccines, or other medical interventions (including licensed products and devices for a purpose other than that for which they were licensed) in humans under a research protocol must be performed under a Food and Drug Administration (FDA) investigational new drug (IND) or investigational device exemption (IDE).

2. Administrative and National Policy Requirements

The following Federal wide and HHS-specific policy requirements apply to awards funded through NIH:

All federal statutes and regulations relevant to federal financial assistance, including those highlighted in NIH Grants Policy Statement Section 4 Public Policy Requirements, Objectives and Other Appropriation Mandates.

By applying for or accepting federal funds from HHS, recipients certify compliance with all federal antidiscrimination laws and these requirements and that complying with those laws is a material condition of receiving federal funding streams. Recipients are responsible for ensuring subrecipients, contractors, and partners also comply.

Applicants and recipients are strongly encouraged to refer to the NIH Director's Statement of Priorities, entitled "Advancing NIH's Mission Through a Unified Strategy." 

Recipients are responsible for ensuring that their activities comply with all applicable federal regulations. Pursuant to 2 CFR 200.340, by accepting an NIH award, the recipient agrees that continued funding for the award is contingent upon the availability of appropriated funds, recipient satisfactory performance, compliance with the Terms and Conditions of the award, and may also otherwise be terminated, to the extent authorized by law, if the agency determines that the award no longer effectuates the program goals or agency priorities, in line with 2 CFR 200.340(a)(4).

Pursuant to the Cybersecurity Act of 2015, Div. N, § 405, Pub. Law 114-113, 6 USC § 1533(d), the HHS Secretary has established a common set of voluntary, consensus-based, and industry-led guidelines, best practices, methodologies, procedures, and processes.

Successful recipients under this NOFO agree that:

When recipients, subrecipients, or third-party entities have:

  • ongoing and consistent access to HHS owned or operated information or operational technology systems; and
  • receive, maintain, transmit, store, access, exchange, process, or utilize personal identifiable information (PII) or personal health information (PHI) obtained from the awarding HHS agency for the purposes of executing the award.

Cybersecurity plans and procedures must at minimum include the following:

  • Develop cybersecurity plans and procedures, modeled after the NIST Cybersecurity framework, to protect HHS systems and data:
    • Identify:
      • Develop an inventory of all assets and accounts with access to HHS owned and operated information or operational technology systems or which obtain PII or PHI for the purposes of the award.
    • Protect:
      • Limit access to HHS owned and operated systems to only those in need of access to complete reward activities.
      • Require all staff to complete annual cybersecurity and privacy awareness training. Visit 405(d): Knowledge on Demand (hhs.gov) to obtain free trainings, if needed.
      • Enable multifactor authentication for all employees, subrecipients, and third-party entities to access HHS owned and operated information or operational technology systems.
      • Regularly backup sensitive data and test backups.
    • Detect:
      • Install anti-virus or anti-malware software on all devices, servers, and accounts used to connect to HHS owned and operated systems.
    • Respond:
      • Develop an incident response plan. See Incident-Response-Plan-Basics_508c.pdf (cisa.gov) to learn about developing incident response plans.
      • Have cybersecurity incident reporting procedures that ensure the relevant HHS awarding agencies are notified of a cybersecurity incident within 48 hours of discovery. A cybersecurity incident is defined as an unplanned interruption to a technology service or reduction in the quality of a technology service, or an occurrence that actually or potentially jeopardizes the confidentiality, integrity, or availability of an information system or the information the system processes, stores, or transmits.
    • Recover:
      • Investigate incidents and plug any security gaps identified. 

All activities proposed in your application and budget narrative must align with applicable law, including but not limited to statutes, executive orders, federal regulations and applicable judicial holdings.  Accordingly, discretionary awards shall not be used to fund, promote, encourage, subsidize, or facilitate; racial preferences or other forms of racial discrimination by the recipient, including activities where race or intentional proxies for race will be used as a selection criterion for employment or program participation; denial by the recipient of the sex binary in humans, or the belief that sex is a chosen or mutable characteristic; illegal immigration; or any other initiatives that compromise public safety.  If an application does not align, the application will not receive funding to the extent permitted by law and applicable court orders.

For applications involving substance abuse, the application must not support harm reduction. Please see Updated Funding Guidance for Recipients on Supplies and Services.

For applications involving funding Medication-Assisted Treatment (MAT) or medications for opioid use disorder (MOUD), this funding should be used to provide comprehensive treatment and recovery support services rather than medication-only models for opioid use disorder. Services should include medications, where clinically indicated, in conjunction with psychosocial and other treatment and recovery support services. Funding can also be used to support individualized tapering and discontinuation of medications when clinically indicated. Please see Updated Funding Guidance for Recipients on  MAT/MOUD.

As of October 1, 2025, HHS has adopted 2 CFR Part 200, with some modifications included in 2 CFR Part 300. These regulations replace those in 45 CFR Part 75. However, for NIH, under the Consolidated Appropriations Act for FY 2026, (P.L. 119-75, Division B, Title II, Sec. 224), the provisions relating to indirect costs in 45 CFR 75 continue to apply to NIH awards. Consistent with the statute, NIH will not apply updated thresholds outlined within 2 CFR Part 200, at this time.

In administering programs under this and all funding announcements, NIH prioritizes: 

  • Research involving rigorous scientific methods, including for studies related to children and adolescents, where NIH is committed to approaches that reflect the highest standards of clinical care and child safety. 
  • Biological and physiological integrity: Recognizing the relevance of biological sex to health outcomes, NIH encourages applicants to account for sex-based health factors in program design, data collection, and service delivery where scientifically appropriate.
  • NIH will implement these priorities consistent with applicable laws, regulations, court orders, and all required administrative procedures. Applicants are encouraged to describe how their proposed programs align with these priorities in their project narratives. Funded activities must advance NIH's vision of protecting and improving the health and well-being of Americans. The particular focus is on those who are medically vulnerable, or live in areas with limited access to care. NIH's duty is to serve wisely, effectively, and with measurable results that justify every taxpayer dollar invested. 

Cooperative Agreement Terms and Conditions of Award

The following special terms of award are in addition to, and not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB) administrative guidelines, U.S. Department of Health and Human Services (HHS) grant administration regulations at 2 CFR Part 200, and other HHS, PHS, and NIH grant administration policies.

The administrative and funding instrument used for this program will be the cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the recipients is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the recipients for the project as a whole, although specific tasks and activities may be shared among the recipients and NIH as defined below.

The PD(s)/PI(s) will have the primary responsibility for:

  • Implementing clinical research protocols for affiliated HIV/AIDS Clinical Trials Network(s).
  • Developing and executing recruitment, enrollment, retention, and long-term follow-up strategies across Clinical Research Sites (CRSs) (and Protocol Specific [PS] sites, if applicable).
  • Engaging and maintaining robust productive relationships with implementation science researchers to support high quality outputs.
  • Ensuring qualified researchers and appropriately trained staff are in place to conduct multicenter HIV/AIDS trials for applicable PS sites.
  • Establishing and overseeing clear organizational structures, communication plans, and SOPs.
  • Managing protocol-specific funding appropriately.
  • Obtaining required NIAID approvals prior to study initiation.
  • Ensuring compliance with federal regulations, FDA, ICH/GCP, NIAID and DAIDS policies, and applicable local and national regulatory requirements. 
  • Complying with Network policies on presentation and publication of findings.
  • Maintaining laboratory standards and certifications and QA programs as appropriate.
  • Overseeing a comprehensive Clinical Quality Management Plan.
  • Collaborating with NIAID by cooperating with NIAID monitoring, auditing, and regulatory reviews and providing timely information requested by NIAID or affiliated Networks.
  • Implementing community partnership and results dissemination plans.
  • Recipients will retain custody of and have primary rights to the data and software developed under these awards, subject to Government rights of access consistent with current HHS, PHS, and NIH policies.

NIH staff have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:

  • Facilitating coordination across NIH-supported Networks and federal agencies.
  • Communicating scientific priorities, track protocol development and study conduct.
  • Participating in meetings, trainings, and scientific discussions.
  • Providing scientific and policy guidance.
  • Supporting community engagement coordination.
  • Overseeing contract resources supporting investigational agents and strategic initiatives.
  • Recommending redirecting or supplementing funds in urgent public health situations.
  • Liaising with pharmaceutical companies and the FDA and ensure trials comply with FDA, ICH/GCP and federal regulations.
  • Providing oversight, including reviewing/approving CRSs prior to study initiation, conducting site visits to assess readiness and compliance, providing required training in regulatory compliance, overseeing safety reporting, reviewing reports and monitoring CTU elements as needed, and recommending suspension of trials/site participation for noncompliance.
  • Reviewing and approving the addition of PS sites prior to study initiation, as applicable, and recommend suspension of trials/site participation for noncompliance.
  • Providing pharmaceutical support for NIAID-sponsored IND/IDE studies, including product supply coordination.
  • Recommending termination or suspension of studies or site participation due to safety risks, noncompliance, ethical concerns, or failure to meet performance standards.
  • Additionally, an agency program official or ICO program director will be responsible for the normal scientific and programmatic stewardship of the award and will be named in the award notice.

Areas of Joint Responsibility include:

  • Participating in protocol teams led by the Leadership and Operations Center (LOC) for protocol development.
  • Providing ongoing oversight and evaluation of clinical trial enrollment, Clinical Research site quality, laboratory performance, and data integrity; audits as needed.
  • Reviewing and strengthening community engagement activities with CTU Community Advisory Board (CAB) participation.
  • Providing ongoing evaluation/performance assessment against defined metrics; corrective actions for underperformance; potential withdrawal of funding for failure to meet standards.
  • Ensuring consultation with independent advisors (excluding award recipient key personnel or collaborators) for external review.

Dispute Resolution:

Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between recipients and NIH may be brought to Dispute Resolution. A Dispute Resolution Panel composed of three members will be convened: a designee of the recipient, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual recipient. This special dispute resolution procedure does not alter the recipient's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and HHS regulation 45 CFR Part 16.

3. Data Management and Sharing

A Data Management and Sharing Plan (DMS Plan) is required for any NIH-funded or conducted research that will generate scientific data. Applicants must submit the DMS Plan at the time of application using the NIH DMS Plan Format Page. The DMS Plan must address the elements in the structured format. Where the DMS Plan Format Page requires a "Yes or No" response, no additional narrative is allowed. 

4. Reporting

When multiple years are involved, recipients will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the NIH Grants Policy Statement Section 8.4.1 Reporting. To learn more about post-award monitoring and reporting, see the NIH Grants & Funding website, see Post-Award Monitoring and Reporting.

A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement Section 8.6 Closeout. NIH NOFOs outline intended research goals and objectives. Post award, NIH will review and measure performance based on the details and outcomes that are shared within the RPPR, as described at 2 CFR Part 200.301.

Section VII. Agency Contacts

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

Application Submission Contacts

eRA Service Desk - Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten submission by the due date, and post-submission issues.

Grants.gov Support Center - Questions regarding Grants.gov registration and services (e.g., Workspace, subscriptions).

Scientific/Research Contact(s)

National Institute of Allergy and Infectious Diseases (NIAID) 
Email: sciops@niaid.nih.gov

Office of AIDS Research (OAR)
Email: OARinfo@nih.gov

National Heart, Lung and Blood Institute (NHLBI)
Email: ctrisgrants@nih.gov
Subject: RFA-AI-28-004

National Institute on Aging (NIA)
Email: NIA-NOFO-Scientific@nih.gov
Please include the NOFO number in the subject line when emailing.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Email: nichd_mpidb_nofos@mail.nih.gov

National Institute of Dental and Craniofacial Research (NIDCR)
Email: NIDCR-Program@nih.gov

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Division of Diabetes, Endocrinology and Metabolic Diseases
Email: NIDDK_DEM@nih.gov 
Division of Digestive Diseases and Nutrition
Email: NIDDK_DDN@nih.gov 
Division of Kidney, Urologic, and Hematologic Diseases
Email: NIDDK_KUH@nih.gov 

National Institute on Drug Abuse (NIDA)
Email: NIDAHIVProgram@mail.nih.gov

National Institute of Mental Health (NIMH)
Email: NIMH.DAR.inquiries@nih.gov

National Institute of Neurological Disorders and Stroke (NINDS)
Email: NINDSNeuroHIV@nih.gov 

Peer Review Contact(s)

Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).

Financial/Grants Management Contact(s)

National Institute of Allergy and Infectious Diseases (NIAID) 
Email: niaidfinancial-grantscontact@mail.nih.gov

Office of AIDS Research (OAR)
Email: OARinfo@nih.gov

National Heart, Lung and Blood Institute (NHLBI)
Email: NHLBIOGMInbox@nhlbi.nih.gov
Subject: RFA-AI-28-004

National Institute on Aging (NIA)
Email: NIA-NOFO-Grants@nih.gov
Please include the NOFO number in the subject line when emailing.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Email: nichdgrantsmanagement@mail.nih.gov

National Institute of Dental and Craniofacial Research (NIDCR)
Email: deeranotifications@nidcr.nih.gov

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Email: NIDDKGMBManagementTeam@niddk.nih.gov 

National Institute on Drug Abuse (NIDA)
Email: nidagmbemail@nida.nih.gov

National Institute of Mental Health (NIMH)
Email: NIMHNOFOGrantsManagement@mail.nih.gov   

National Institute of Neurological Disorders and Stroke (NINDS)
Email: ChiefGrantsManagementOfficer@ninds.nih.gov

Section VIII. Other Information

Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Authority and Regulations

Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.